Connect Biopharma initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Connect Biopharma with an Outperform rating and $8 price target. Connect Biopharma is a single-asset story built on rademikibart, a next-generation human IgG4 anti-interleukin-4 receptor alpha antibody that binds with higher affinity than dupilumab and, uniquely in the class, drives receptor-independent bronchodilation via pHSP20, producing FEV1 gains within 15 minutes through IV formulation. That speed could allow rademikibart to enter the acute exacerbation setting no current biologic is approved, the firm notes. FDA-aligned 28-day treatment-failure endpoint, which could then bridge patients into chronic maintenance where value concentrates. Oppenheimer highlights the two Phase 2 Seabreeze STAT studies read out in second half of 2026, the asthma topline in early September, as the valuation-inflection event.
Oppenheimer initiated coverage of Connect Biopharma with an Outperform rating and $8 price target.
Connect Biopharma is a single-asset story built on rademikibart, a next-generation human IgG4 anti-interleukin-4 receptor alpha antibody that binds with higher affinity than dupilumab and, uniquely in the class, drives receptor-independent bronchodilation via pHSP20, producing FEV1 gains within 15 minutes through IV formulation.
That speed could allow rademikibart to enter the acute exacerbation setting no current biologic is approved, the firm notes.
FDA-aligned 28-day treatment-failure endpoint, which could then bridge patients into chronic maintenance where value concentrates.
Oppenheimer highlights the two Phase 2 Seabreeze STAT studies read out in second half of 2026, the asthma topline in early September, as the valuation-inflection event.